FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/04/065220 [Registered on: 04/04/2024] Trial Registered Prospectively
Last Modified On: 03/04/2024
Post Graduate Thesis  No 
Type of Trial  Observational 
Type of Study   Prospective cohort study 
Study Design  Other 
Public Title of Study   Determining the influence of mode of delivery on the immune system of the infant  
Scientific Title of Study   IDENTIFYING THE EFFECT OF MODE OF DELIVERY ON THE IMMUNE STATUS OF THE INFANT 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr M M Patil 
Designation  HOD, Dept. of Paediatrics 
Affiliation  Shri B M Patil Medical Collage and Hospital, BLDE(DU) 
Address  Dept. of Paediatrics, Shri B M Patil Medical Collage and hospital, BLDE(DU), Vijaypura

Bijapur
KARNATAKA
586103
India 
Phone  9900291825  
Fax    
Email  mm.patil@bldedu.ac.in  
 
Details of Contact Person
Scientific Query
 
Name  Dr M M Patil 
Designation  HOD, Dept. of Paediatrics 
Affiliation  Shri B M Patil Medical Collage and Hospital, BLDE(DU) 
Address  Dept. of Paediatrics, Shri B M Patil Medical Collage and hospital, BLDE(DU), Vijaypura


KARNATAKA
586103
India 
Phone  9900291825  
Fax    
Email  mm.patil@bldedu.ac.in  
 
Details of Contact Person
Public Query
 
Name  Dr M M Patil 
Designation  HOD, Dept. of Paediatrics 
Affiliation  Shri B M Patil Medical Collage and Hospital, BLDE(DU) 
Address  Dept. of Paediatrics, Shri B M Patil Medical Collage and hospital, BLDE(DU), Vijaypura


KARNATAKA
586103
India 
Phone  9900291825  
Fax    
Email  mm.patil@bldedu.ac.in  
 
Source of Monetary or Material Support  
Shri B M Patil Medical Collage Hospital and research centre, BLDE(DU) 
 
Primary Sponsor  
Name  Shri B M Patil Medical Collage Hospital and research centreBLDEDU 
Address  Shri B M Patil Medical Collage Hospital and research centre, BLDE(DU), Smt. Bangaramma Sajjan Campus Solapur Road, Vijaypura - 586103 
Type of Sponsor  Private medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr M M Patil  Shri B M Patil Medical Collage hospital and research centre  Pediatrics OPD, Department of Pediatrics
Bijapur
KARNATAKA 
9900291825

mm.patil@bldedu.ac.in 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethical Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Healthy Human Volunteers  Immune status  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  NIL  NIL 
Comparator Agent  NIL  NIL 
 
Inclusion Criteria  
Age From  0.00 Day(s)
Age To  6.00 Month(s)
Gender  Both 
Details  40 Newborn babies will be included in the study.
Group A - 20 healthy infants delivered through caesarean section delivery
Group B - 20 healthy infants delivered through normal vaginal delivery. 
 
ExclusionCriteria 
Details  neonates whose mothers did not give concent
prematurely born infants
deliveries of unknown gestational age
infants with congenital anomalies or known genetic diseases
infants exposed to antibiotics in the first week of life
infants with breastfeeding difficulties or requiring food  
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
FOXP3 Gene expression measured by PCR  At Birth
3 month
6 month 
 
Secondary Outcome  
Outcome  TimePoints 
none  none 
 
Target Sample Size   Total Sample Size="120"
Sample Size from India="120" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   15/04/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   Introduction 




Newborns’ overall health and lifetime development are greatly influenced by their mode of delivery which influences their gut flora and has an effect on their short- and long-term well-being. The immune system, mental health issues, and metabolic diseases have all been associated with abnormalities gut microbiota, highlighting the critical role that gut microbiota plays in determining one’s quality oflife. The gut microbiota functions as an extension of the host genome, containing 50-100 times more genes than the host and providing vital enzymes that the host is unable to manufacture. Many disorders can result from any changes in this microbial mix, known as dysbiosis.

The mode of delivery along with other factors like feeding schedule have a significant impact on an infant’s gut microbiome health.Delivery methods such as vaginal and caesarean sections are crucial in determining the microbiological makeup. Because lactobacilli are so prevalent in the vagina, newborns delivered vaginally have higher than average quantities of these bacteria. On the other hand, babies born by caesarean section have lower microbe counts from the bacteroides, genus.

The mode of delivery related differences in the composition of the gut microbiota is closely related to the establishment and development of the neonates immune system. Research has indicated that the gut microbiota plays a significant role in controlling the immune system, and it has been linked to allergic and hypersensitive reactions via affecting the expression of the genes including FOXP3 CTLA4, GATA3, IKZF2, IFNG, IL10RA, and TGFB1 gene.

So, this work deliberately focuses on important genes-CTLA4, FOXP3, GATA3, IKZF2, IFNG, IL10RA, and TGFB1-that are known to affect immune regulation and response. Immunological homeostasis is maintained by CTLA4, a crucial regulator of T-cell activation that sheds light on the fine balance between tolerance and immunological response. The project’s focal point, FOXP3, serves as a pivotal player in the development of the immune system and is particularly linked to regulatory T cells (Treg). It provides insight into the complex interplay that occurs between the gut microbiota and immune regulation. The greater influence of gut microbiota on immune cell development is shown by GATA3, a crucial component in T-cell differentiation. The transcription factor IKZF2’s participation provides insight into how gut microbiota may affect the genetic machinery responsible for immune cell specification. The foundation of immune responses, IFNG, sheds light on the complex interplay between gut microbiota and the maturation of efficient immune defence systems. The anti-inflammatory cytokine IL-10 receptor, or IL10RA, provides insight into possible regulatory pathways by which the gut microbiota may affect immune responses and the finely balanced relationship between inflammation and tolerance. The investigation focuses on how gut microbiota may influence signalling cascades essential for immune systemdevelopment is furthered by the discovery of

TGFB1, a crucial regulator of immune cell activity. We will also be looking into the central focus of our study FOXP3 gene expression in T cells by flowcytometric measurement and quantification. This will be performed by using extracellular and intracellular fluorochrome markers to identify the cell populations showing increased FOXP3 gene expression which will provide further insights into the immune status of the infant. So, this work aims to decipher the complex genetic patterns influencing immunological development in neonates by synthesising these genetic aspects with the mode of delivery. Understanding the complex interactions among the host genome, gut microbiota, and immune system helps advance our understanding of the factors that influence health in the early years of life.






Study Design: A Prospective Cohort study

Sample Size: 40 Newborn babies will be included in the study.

Group A: 20 healthy infants delivered through caesarean section delivery.

Group B: 20 healthy infants delivered through normal vaginal delivery.


Inclusion & Exclusion Criteria :

Inclusion Criteria: All consenting individuals born in BLDE (DU)’s Shri B M Patil Medical Collage, Hospital & Research Centre who are breast fed will be included in the study.

Exclusion Criteria:

Those neonates whose mothers not willing to give consent.

Deliveries of unknown gestational age

Babies with known health conditions that may interfere with the gut microbiota and immune functions of the infant will be excluded from the study.

Who are not breast fed born to mothers with known health conditions with known infectious diseases, congenital anomalies, metabolic diseases.


Written Consent: Written informed consent will be obtained from all the participants before enrolment.


Study Protocol:

• Gene Expression Studies:

Extracting RNA:

5ml of blood samples will be collected in EDTA tubes from infant delivered after the 36 weeks gestation, after 03 months and 06 months of age.

To extract RNA, use TRIzol.

Analysis of the purity and concentration of RNA.

Specific primers will be designed for FOXP3, CTLA4, GATA3, IKZF2, IFNG, IL10RA, and TGFB1. Use FOXP3, CTLA4, GATA3, IKZF2, IFNG, IL10RA, and TGFB1 primers and CDNA will be synthesised to do PCR.

Electrophoresis of gels:

Examination of the PCR results will be done by using an agarose gel.

Relative expression of FOXP3, CTLA4, GATA3, IKZF2, IFNG, IL10RA, and TGFB1 will be done by aPCR.

Statistical Analysis:

Statistical analysis will be done in SPSS software.

In gene expression plots, fold change is plotted, but statistical analysis will be made on threshold cycle (ACt) values. The p values<0.05 will be considered significant.

Sequencing data analysis

Multivariate ANOVA (PERMANOVA) will be used to evaluate group differences based on UniFrac distance matrices. Differences were considered significant at P<0.05.



 
Close